Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Like clockwork!
Well, if you didn’t take advantage of the dips along the way to average down, then that’s on you. The FACT is the stock price has performed exceptionally well since the start of 2020. I took advantage of the dips and am very happy with the performance over the last 18 months. Sorry if you didn’t, but over that period, the stock has been blockbuster.
Facts:
The share price is up nearly 5% year to date and was up over 100% in 2020. Those are are facts, regardless of what the share price was in 2018 or what your cost basis is.
You know full well they have absolutely no control over the REMOVE study and no honest person could hold them responsible for the delay in the results. To continually imply in a public forum that management has dropped the ball on this is disingenuous at best and a despicable, blatant lie at worst.
Whine, whine, whine. AEMD is down about 99+% over the last 10 years. Funny that you don’t mention that.
I only stop by here on a significant down day for a laugh and nothing’s changed. Whine, whine, whine…
Whine, whine, whine…
There was no $57 million loan. That’s just false. Additionally, they just announced a lease for their new global headquarters, not a new manufacturing facility. Your entire post is false and misleading.
Thank you. I saw that on the ST board as well. If you’re satisfied, then I’m satisfied.
“Should we be concerned?” about what?
Obviously, you’re not affecting the share price because it’s gained massively during all your efforts to depress it. My comments were tongue-in-cheek, also obviously.
Thanks! Have a great weekend.
We don’t trade 2.2 million shares based on Blackrock’s disclosure. This is not the reason for today’s action.
You continue to sound like an incessantly crying baby. Maybe that’s why most of the non-whiners have moved on to other forums. I tried to stick around, but now it’s become an absolutely ridiculous and lifeless forum here. Good luck to you all on the dark side and don’t forget to take your meds daily.
Speculation that the company has the data with no evidence whatsoever of that is irresponsible. Hey, they may or may not have it, but to even suggest that they do and that may suggest bad news is reckless, unless you have evidence. Have you noticed that Techxen doesn’t post here anymore? I wonder why...
Whether you like it or not, it was up 107%! That makes it my best performing stock of 2020 and one of the best performing stocks of the year. It doesn’t matter whether you like it or not or what your cost basis is, it’s a fact. If you didn’t average down during the $3’s, 4’s, 5’s and 6’s, well that’s your issue. But overall, the fact is that this stock brought a massive return in 2020 and management should be rewarded for a great 2020! But you and the others here are willingly blinded to anything positive because you’re emotional. I deal in facts, not emotion.
“Will liquidate most of my position on Monday.”
Other than the massive gain for CTSO in 2020, this is the best news I’ve heard in quite some time. May we have this notarized?
Congratulations on a fantastic return this year with CTSO: up 107%!!! May our good fortune at least repeat itself in 2021! I hope you all averaged your cost down earlier in the year. Happy New Year!
I rest my case.
Nope, that's not it. I still look around here, but there's too much of the chronic complaining and virtually nonexistent substantive discussion. It's become tiresome and dysfunctional.
AEMD has been very good at shareholder dilution for many years, but had never gotten anything to market after trying for a couple decades. I wouldn’t worry about an early in vitro study at this point.
This is why most of the prime posters have left this board.
What road is who taking? What con job?
The piece is a huge bunch of BS, in my opinion, mainly because they put nearly all emphasis on current sequential quarterly growth based in part on Covid revenues. I wouldn’t care if we had zero Covid revenues now because the real value of Covid for us is not the current revenues related to it, but the increasing recognition of our technology as life-saving in multiple indications. The real value driver in the near term is FDA approval to remove Ticagrelor, then others to follow. The piece is absolutely absurd and should be ignored, in my opinion.
Right on cue, Mike!
I'm honored that you miss me! I've been checking in now and then, but have been very busy. Today's release was great. Record revenues are always a good thing, although you know I don't care all that much about quarterly revenues at this point. What matters is the path to fulfilling enormous potential and this team is doing all the right things to lead us there. As I've said in the past, for sure it's taken much longer than we had hoped, but as each quarter goes by, we are incrementally better positioned. From this release, I believe we are in our best position ever and are poised to move significantly higher very soon.
I see Cytosorbents listed, but it's not a sepsis diagnostic. It's a sepsis treatment.
It's just a few shares; nothing significant.
What are "apples and oranges people"?
Seriously, blaming the CEO for nearly every daily drop in share price is absolutely ridiculous. I notice you don’t “blame” him when it rises on any given day, like the day before yesterday. Your chronic, multi-board incessant, irrational negativity brings your motives into question.
Well there goes the piano...
Reroute to the Regeneron board.
I agree. I want to know yesterday! But one cannot hold the company accountable for the FDA's dragging their feet.
I agree. But the FDA works on the FDA’s timeline, not that of impatient investors or the companies whose products they’re evaluating. Why anyone would bash the company for not receiving FDA feedback yet is beyond the bounds of reason (not saying you did, but others here do).
If your numbers are correct, then TODAY’S valuation of a yet-to-be-approved therapeutic is nearly 9 times 2025 revenues. Today, Cytosorbents, which has enormous potential, is valued at around 9 times estimated 2020 (today’s) annual revenue. I believe our potential should have us much higher now and that has nothing to do with current quarterly revenues. Potential approval and potential revenues are what eventually drives share price for legitimate biotechs with massive potential, which I believe includes Cytosorbents. That it hasn’t happened yet is not relevant.
This is why our quarterly revenues are not as important as most here think they are YET. What is important is the company’s potential after FDA approval for any indication. People here cannot seem to see through the one dimensional idea of quarterly revenues at this stage. It’s not reasonable to concentrate on the traditional metrics used to evaluate mature biotechs that have FDA approval. There is enormous potential here, in my opinion, and I’m pleased they don’t send out fluff PR’s twice a week, as some here seem to want.
It's up because of ONE case report! Talk about needing more data!
So you're asking me if some doctors you saw on television know about Cytosorb? Now how would I know that unless I were one of them? There are hundreds of approved and investigational therapeutics for Covid infection and sequelae. And you're wondering why a random doctor you saw on television didn't mention Cytosorb? Sorry, it's jut not reasonable to bring this up on a public forum unless you have an underlying and unapparent reason for doing so. I know you're a smart person, but such questions and musings do not comport with that assessment.
Why don’t you ask them? It’s a bit off the topic at hand, given that the President is not critically ill, so I’m not sure why you think media doctors should be discussing Cytosorb at this point other than to softly plant more negativity. Cytosorb does not prevent cytokine storm. It attenuates it.